PDL BIOPHARMA, INC. (PDLI) is a publicly traded company in the Unknown sector. Across all available filings, 46 corporate insiders have executed 708 transactions totaling $56.1M, demonstrating a bullish sentiment with $9.2M in net insider flow. The most recent transaction on Feb 1, 2021 involved a purchase of 187,061 shares valued at $383.5K.
No significant insider buying has been recorded for PDLI in the recent period.
No significant insider selling has been recorded for PDLI in the recent period.
Based on recent SEC filings, insider sentiment for PDLI is bullish with an Insider Alignment Score of 58/100 and a net flow of $9.2M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at PDL BIOPHARMA, INC. (PDLI) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 46 insiders are actively trading PDLI stock, having executed 708 transactions in the past 90 days. The most active insider is Point Capital L.p. Silver (Executive), who has made 5 transactions totaling $20.3M.
Get notified when executives and directors at PDLI file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 1, 2021 | Capital L.p. Silver Point | Executive | Purchase | 187,061 | $2.05 | $383.5K | |
| Dec 30, 2020 | Capital L.p. Silver Point | Executive | Purchase | 6,325,213 | $2.50 | $15.8M | Large |
| Dec 30, 2020 | W. Gryska David | Executive | Sale | 20,000 | $2.74 | $54.8K | |
| Dec 29, 2020 | J. O'shea Robert | Executive | Purchase | 268,600 | $2.69 | $722.5K | Large |
| Dec 28, 2020 | J. O'shea Robert | Executive | Purchase | 235,000 | $2.70 | $634.5K | Large |
| Dec 24, 2020 | J. O'shea Robert | Executive | Purchase | 128,000 | $2.65 | $339.2K | |
| Dec 23, 2020 | Capital L.p. Silver Point | Executive | Purchase | 485,000 | $2.60 | $1.3M | Large |
| Dec 22, 2020 | Peter Mclaughlin John | Executive | Sale | 277,934 | $2.61 | $725.4K | Large |
| Dec 22, 2020 | Capital L.p. Silver Point | Executive | Purchase | 850,000 | $2.59 | $2.2M | Large |
| Dec 21, 2020 | Peter Mclaughlin John | Executive | Sale | 50,000 | $2.62 | $131.0K | |
| Dec 21, 2020 | Capital L.p. Silver Point | Executive | Purchase | 230,000 | $2.63 | $604.9K | Large |
| Dec 17, 2020 | A. Mule Edward | Executive | Purchase | 398,000 | $2.61 | $1.0M | Large |
| Dec 16, 2020 | W. Gryska David | Executive | Sale | 75,000 | $2.68 | $201.0K | |
| Dec 16, 2020 | Monnet Dominique | Executive | Sale | 500,000 | $2.60 | $1.3M | Large |
| Dec 16, 2020 | Lewis Stone Christopher | Executive | Sale | 200,000 | $2.56 | $512.0K | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 77 | $32.6M | 37.4% |
Sale(S) | 362 | $23.4M | 26.8% |
Award(A) | 129 | $19.5M | 22.3% |
Exercise(M) | 104 | $8.4M | 9.6% |
Payment(F) | 22 | $3.3M | 3.8% |
Disposition(D) | 14 | $0 | 0.0% |
Insider activity at PDL BIOPHARMA, INC. shows mixed signals across all time. While $32.6M in purchases indicates some executive confidence,$23.4M in sales balances the picture, resulting in a modest net flow of $9.2M.46 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Point Capital L.p. Silver, has transacted $20.3M during this period.